EAM
FOLD

Eventide Asset Management’s Amicus Therapeutics FOLD Stock Holding History

Eventide Asset Management’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-1,950,000
Closed -$15.6M – 123
2019
Q3 		$15.6M Hold
1,950,000
– – 0.52% 64
2019
Q2 		$24.3M Buy
1,950,000
+335,000
+21% +$4.25M 0.74% 50
2019
Q1 		$22M Buy
1,615,000
+279,000
+21% +$3.41M 0.76% 51
2018
Q4 		$12.8M Buy
1,336,000
+636,000
+91% +$6.99M 0.57% 61
2018
Q3 		$8.46M Buy
+700,000
New +$9.79M 0.31% 83

Other funds holding FOLD

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Eventide Asset Management's FOLD Position: Q4 2019 in Review

Eventide Asset Management sold out of Amicus Therapeutics (FOLD) in Q4 2019, closing a stake of 1,950,000 shares — an estimated $15.6M sold.

Eventide Asset Management first reported a position in FOLD in Q3 2018 and held it in 5 quarters. The position peaked at $24.3M in Q2 2019. 224 funds tracked by Wall St. Rank hold FOLD as of Q4 2019.

  • Eventide Asset Management reported no remaining Amicus Therapeutics position as of Q4 2019 after selling out during the quarter.
  • Eventide Asset Management sold 1,950,000 Amicus Therapeutics shares in Q4 2019, an estimated $15.6M.
  • Eventide Asset Management first reported a position in Amicus Therapeutics in Q3 2018 and held it in 5 quarters.
  • Eventide Asset Management's Amicus Therapeutics position peaked at $24.3M in Q2 2019.
  • 224 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q4 2019.

Based on Eventide Asset Management's 13F filing for Q4 2019, filed 29 Jan 2020.